Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 26 September 2025 are set out below…
The Federal Court of Australia has handed down judgment in proceedings between Perfect Day, Inc. and the Commissioner of Patents, in an appeal from an opposition decision concerning a patent application for dairy substitute food compositions. Justice Rofe dismissed Perfect Day’s appeal and refused to allow the application to proceed to grant, finding that the claims failed to meet the heightened support and sufficiency requirements introduced under the ‘Raising the Bar’ amendments.
Justice Moshinsky of the Federal Court has delivered judgment in patent proceedings between The NOCO Company (NOCO) and Brown & Watson International Pty Ltd (B&W) relating to portable vehicle battery jump starters.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 26 September 2025 are set out below…
It’s not often that the Australian Registrar of Trade Marks looks at disclaimers (which were a thing before the Trade Marks Act 1995 (Cth) came into force), but Hunchy Hills Distillery Pty Ltd [2025] ATMO 180 delivered by Hearing Officer Nicole Worth on 5 September 2025 is one such case.
Regeneron and Bayer have moved swiftly to appeal Justice Rofe’s decision denying Regeneron and Bayer’s application for PI on MOT patent AU2012205599…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 19 September 2025 are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the fortnight ending 12 September are set out below…
Pearce IP’s CEO, Naomi Pearce, discusses changes in New Zealand High Court procedure with our Head of Litigation (NZ), Paul Johns. As those changes are based on similar reforms made earlier in Australia, light is shed on their potential effects by the Head of Litigation (Australia), Helen Macpherson.
No interlocutory injunction (‘preliminary injunction’ or ‘PI’) has been granted in any pharmaceutical patent dispute since 2018. The Federal Court’s refusal last week of Regeneron and Bayer’s PI
Pearce IP is Australasian Lawyer and NZ Lawyer’s 5-Star Employer of Choice & “Standout Winner” for Inclusion and Culture (<100 employees)
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 29 August are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the fortnight ending 22 August are set out below…
In a unanimous decision, Justices Burley, Rofe and Downes of the Full Court of the Federal Court have dismissed Novartis’ appeal against the first instance decision of Justice Yates who found that Pharmacor’s…
Naomi Pearce Ranked Among the World’s Leading IP Strategists in IAM Strategy 300
In a unanimous decision, Justices Burley, Rofe and Downes of the Full Court of the Federal Court have dismissed Novartis’ appeal against the first instance decision of Justice Yates who found that Pharmacor’s…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 8 August are set out below…
Pearce IP’s Head of Litigation (NZ), Paul Johns, and Head of Trade Marks, Kimberley Evans, discuss the third party “revival” of the ANSETT brand in 2025 for travel agency services, more than 20 years after the airline folded.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 1 August are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 25 July are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 18 July are set out below…
A new development in New Zealand will provide an option for a faster route to judgment in patent and other intellectual property litigation. From 1 October 2025, a Commercial…
In this PiPCast™, Pearce IP’s Head of Trade Marks, Kimberley Evans, speaks to CEO, Naomi Pearce, about current trade mark examination trends in Australia and New Zealand.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 11 July are set out below…
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
